{"protocolSection":{"identificationModule":{"nctId":"NCT07090330","orgStudyIdInfo":{"id":"ORKA-001-112"},"organization":{"fullName":"Oruka Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis","officialTitle":"A Multicenter, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ORKA-001 in Participants With Moderate-to-Severe Plaque Psoriasis","acronym":"EVERLAST-A"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2025-07-18","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-09","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-05","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-07-21","studyFirstSubmitQcDate":"2025-07-21","studyFirstPostDateStruct":{"date":"2025-07-29","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-30","lastUpdatePostDateStruct":{"date":"2025-11-03","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Oruka Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a multicenter, randomized, double-blinded, placebo-controlled, proof-of-concept study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.","detailedDescription":"This is a proof-of-concept study evaluating ORKA-001 in patients with moderate-to-severe psoriasis with study drug administration divided into an Induction period followed by a Maintenance period. Following completion of the Maintenance period at Week 52, participants will have the option to enter into the open-label extension (OLE) study."},"conditionsModule":{"conditions":["Plaque Psoriasis"],"keywords":["Phase 2","ORKA-001","Plaque psoriasis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":80,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"(Induction Period) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Induction regimen.","interventionNames":["Drug: ORKA-001 Induction Dose"]},{"label":"(Induction Period) Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive Placebo per protocol Induction regimen.","interventionNames":["Other: Placebo"]},{"label":"(Maintenance Period - Arm 1) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Drug: ORKA-001 Maintenance Dose"]},{"label":"(Maintenance Period - Arm 2) ORKA-001","type":"EXPERIMENTAL","description":"Participants will receive ORKA-001 per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Drug: ORKA-001 Maintenance Dose"]},{"label":"(Maintenance Period - Arm 3) Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"DRUG","name":"ORKA-001 Induction Dose","description":"ORKA-001 Induction Dose, administered by subcutaneous (SC) injection","armGroupLabels":["(Induction Period) ORKA-001"]},{"type":"OTHER","name":"Placebo","description":"Placebo administered by subcutaneous (SC) injection","armGroupLabels":["(Induction Period) Placebo","(Maintenance Period - Arm 3) Placebo"]},{"type":"DRUG","name":"ORKA-001 Maintenance Dose","description":"ORKA-001 Maintenance Dose, administered by subcutaneous (SC) injection","armGroupLabels":["(Maintenance Period - Arm 1) ORKA-001","(Maintenance Period - Arm 2) ORKA-001"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 16"}],"secondaryOutcomes":[{"measure":"Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16","description":"Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 16"},{"measure":"Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 52","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 52","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 52","description":"The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).","timeFrame":"Week 52"},{"measure":"Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 52","description":"The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).","timeFrame":"Week 52"},{"measure":"Incidence of Treatment-emergent Adverse Events","description":"Incidence of treatment adverse events and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms","timeFrame":"Day 1 through 52 Weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Participants ≥ 18 years of age\n2. Have a diagnosis of plaque psoriasis for \\> 6 months\n3. Have moderate-to-severe chronic plaque psoriasis defined as:\n\n   1. BSA ≥ 10%, and\n   2. PASI ≥ 12, and\n   3. IGA score of ≥ 3 on a 5-point scale\n4. Candidate for systemic therapy or phototherapy\n5. Women of childbearing potential must have a negative pregnancy test\n\nExclusion Criteria:\n\n1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis\n2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease\n3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence\n4. A known hypersensitivity to any components of the ORKA-001 drug product\n5. Women who are breastfeeding or plan to breastfeed during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Oruka Clinical Trials Information","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"locations":[{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Fountain Valley","state":"California","zip":"92708","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":33.70918,"lon":-117.95367}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90045","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"San Diego","state":"California","zip":"92123","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Santa Ana","state":"California","zip":"92701","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":33.74557,"lon":-117.86783}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Santa Monica","state":"California","zip":"90404","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":34.01949,"lon":-118.49138}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Cromwell","state":"Connecticut","zip":"06416","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":41.5951,"lon":-72.64537}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Coral Gables","state":"Florida","zip":"33134","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":25.72149,"lon":-80.26838}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Rolling Meadows","state":"Illinois","zip":"60008","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.08419,"lon":-88.01313}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Bowling Green","state":"Kentucky","zip":"42104","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":36.99032,"lon":-86.4436}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Rockville","state":"Maryland","zip":"20850","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":39.084,"lon":-77.15276}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02111","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Detroit","state":"Michigan","zip":"48202","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.33143,"lon":-83.04575}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"New York","state":"New York","zip":"10023","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"New York","state":"New York","zip":"10029","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Portland","state":"Oregon","zip":"97201","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Norfolk","state":"Virginia","zip":"23502","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":36.84681,"lon":-76.28522}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Milwaukee","state":"Wisconsin","zip":"53226","country":"United States","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T5J 3S9","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Edmonton","state":"Alberta","zip":"T6G 1C3","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":53.55014,"lon":-113.46871}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Surrey","state":"British Columbia","zip":"V3R 6A7","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":49.10635,"lon":-122.82509}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Hamilton","state":"Ontario","zip":"L8N 1Y2","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.25011,"lon":-79.84963}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"London","state":"Ontario","zip":"N6H 5LS","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":42.98339,"lon":-81.23304}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Markham","state":"Ontario","zip":"L3P 1X3","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.86682,"lon":-79.2663}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Peterborough","state":"Ontario","zip":"K9J 5K2","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":44.30012,"lon":-78.31623}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Toronto","state":"Ontario","zip":"M4W 2N4","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Oruka Therapeutics Investigative Site","status":"RECRUITING","city":"Waterloo","state":"Ontario","zip":"N2J 1C4","country":"Canada","contacts":[{"name":"Oruka Investigative Site","role":"CONTACT","phone":"781-560-0299","email":"clinicaltrials@orukatx.com"}],"geoPoint":{"lat":43.4668,"lon":-80.51639}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"}},"hasResults":false}